iTeos Therapeutics (NASDAQ:ITOS – Get Free Report) and enGene (NASDAQ:ENGN – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, risk, earnings, institutional ownership and dividends.
Volatility and Risk
iTeos Therapeutics has a beta of 1.38, indicating that its stock price is 38% more volatile than the S&P 500. Comparatively, enGene has a beta of -0.65, indicating that its stock price is 165% less volatile than the S&P 500.
Insider & Institutional Ownership
97.2% of iTeos Therapeutics shares are held by institutional investors. Comparatively, 64.2% of enGene shares are held by institutional investors. 12.5% of iTeos Therapeutics shares are held by company insiders. Comparatively, 13.7% of enGene shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| iTeos Therapeutics | N/A | -20.11% | -17.50% |
| enGene | N/A | -16.69% | -14.27% |
Valuation & Earnings
This table compares iTeos Therapeutics and enGene”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| iTeos Therapeutics | $35.00 million | 7.66 | -$112.64 million | ($3.15) | -2.33 |
| enGene | N/A | N/A | -$55.14 million | ($0.58) | -10.52 |
enGene has lower revenue, but higher earnings than iTeos Therapeutics. enGene is trading at a lower price-to-earnings ratio than iTeos Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of recent ratings and price targets for iTeos Therapeutics and enGene, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| iTeos Therapeutics | 0 | 0 | 4 | 0 | 3.00 |
| enGene | 0 | 1 | 8 | 1 | 3.00 |
iTeos Therapeutics presently has a consensus price target of $22.25, indicating a potential upside of 203.13%. enGene has a consensus price target of $25.89, indicating a potential upside of 324.41%. Given enGene’s higher probable upside, analysts plainly believe enGene is more favorable than iTeos Therapeutics.
Summary
enGene beats iTeos Therapeutics on 8 of the 12 factors compared between the two stocks.
About iTeos Therapeutics
iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.
About enGene
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
Receive News & Ratings for iTeos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iTeos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
